4D Molecular Therapeutics, Inc.
FDMT Healthcare Biotechnology
4D Molecular Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 230,194.6% from fiscal 2024. In the quarter to June 2026, revenue grew 25,106.7%, EPS fell 6.12% and free cash flow fell 61.3%, each against the same quarter a year earlier.
Follow FDMT
4D Molecular Therapeutics, Inc. (FDMT) EV/Sales
As of 16 October 2026, 4D Molecular Therapeutics, Inc. (FDMT) trades at a EV/Sales of 5.6×. Over the past ten years it has ranged from −10,857× (December 2024) to 6,149× (September 2024); the current reading is higher than 31% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.5× | — |
| FY2024 | −3,037× | — |
| FY2023 | 26.8× | (82.07%) |
| FY2022 | 149× | 617.29% |
| FY2021 | 20.8× | — |
| FY2020 | −0.7× | — |
| FY2019 | 9.7× | 0.00% |
| FY2018 | 9.7× | 0.00% |
| FY2017 | 9.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.4× | 123.14% |
| Mar 2026 | 2.9× | 461.17% |
| Dec 2025 | 0.5× | (99.97%) |
| Sep 2025 | 1,623× | — |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IVA Inventiva S.A. Sponsored ADR compare | −0.1× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | n/m |
| SANA Sana Biotechnology, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. | 5.6× |
| LXRX Lexicon Pharmaceuticals, Inc. compare | 12.8× |
| OABI OmniAb, Inc. compare | 14.0× |
| ACHV Achieve Life Sciences, Inc. compare | 27.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)